Comet Therapeutics (formerly TM3) was founded in April 2017 in The Netherlands. The company focused on the treatment of orphan neurological disorders through Coenzyme-A substitution therapy strategies.
In 2021, VectivBio Holding AG (VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, acquired Comet Therapeutics, significantly expanding VectivBio’s rare disease pipeline.
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.